The HGH and IGF-1 Axis — How Growth Hormone Drives Its Own

Growth hormone research that focuses on GH levels alone misses a critical layer of the biology: most of GH's documented anabolic effects in research are mediated not by GH directly, but by insulin-like growth factor 1 (IGF-1) produced in response to GH signaling — primarily in the liver, though local IGF-1 production in muscle and bone also contributes.

The Somatotropic Axis

The complete signaling cascade runs: hypothalamus → GHRH → pituitary → GH → liver → IGF-1 → target tissues. Growth hormone binds the GH receptor on hepatocytes, activating JAK2-STAT5 signaling and upregulating IGF-1 gene expression. The resulting circulating IGF-1 then drives the downstream tissue effects — protein synthesis, cell proliferation, glucose uptake — that most GH research is ultimately measuring.

Why IGF-1 Is the Primary Research Endpoint

Because GH is secreted in pulses that produce transient circulating spikes before returning to baseline, GH alone is a difficult biomarker to track in research. IGF-1, by contrast, has a longer half-life and more stable circulating levels that better reflect cumulative GH activity over time — which is why IGF-1 is typically the primary biomarker used to assess GH axis activity in research rather than GH levels themselves.

Direct vs Mediated GH Effects

GH does have some direct effects independent of IGF-1 — including lipolytic effects in adipose tissue and insulin-antagonizing effects on glucose metabolism — that are useful to distinguish from IGF-1-mediated anabolic effects when designing mechanistic research. Researchers studying body composition or metabolic effects may need to account for both direct and IGF-1-mediated pathways.

Research Use Only. DisclaimerFor laboratory and research use only. Not for human consumption. This content is educational and does not constitute medical advice.